Integrin α10β1-selected mesenchymal stem cells reduced hypercoagulopathy in a porcine model of acute respiratory distress syndrome.
Edström D., Niroomand A., Stenlo M., Uvebrant K., Bölükbas DA., Hirdman G.
Clinical Trial on Immune Modulation, published in Respir Res (2023) — summary generated from the PubMed abstract.
Several human studies show positive signals, while research methods and sample sizes continue to develop.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Clinical Trial
- Journal
- Respir Res (2023)
- Country
- England
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 37259141
- PMCID
- PMC10230488
- DOI
- 10.1186/s12931-023-02459-6
- Citations
- 2
Abstract (original English)
Mesenchymal stem cells (MSCs) have been studied for their potential benefits in treating acute respiratory distress syndrome (ARDS) and have reported mild effects when trialed within human clinical trials. MSCs have been investigated in preclinical models with efficacy when administered at the time of lung injury. Human integrin α10β1-selected adipose tissue-derived MSCs (integrin α10β1-MSCs) have shown immunomodulatory and regenerative effects in various disease models. We hypothesized that integrin α10β1 selected-MSCs can be used to treat a sepsis-induced ARDS in a porcine model when administering cells after established injury rather than simultaneously. This was hypothesized to reflect a clinical picture of treatment with MSCs in human ARDS. 12 pigs were randomized to the treated or placebo-controlled group prior to the induction of mild to moderate ARDS via lipopolysaccharide administration. The treated group received 5 × 10 6 cells/kg integrin α10β1-selected MSCs and both groups were followed for 12 h. ARDS was confirmed with blood gases and retrospectively with histological changes. After intervention, the treated group showed decreased need for inotropic support, fewer signs of histopathological lung injury including less alveolar wall thickening and reduction of the hypercoagulative disease state. The MSC treatment was not associated with adverse events over the monito
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Several human studies show positive signals, while research methods and sample sizes continue to develop.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level ASystematic ReviewEurope PMC
The suitability of mesenchymal stem cells for treating immune-mediated inflammatory skin diseases: a systematic review
Systematic Review with a reported sample of 609 on Hair Loss, Immune Modulation, Autoimmune Research, published in Dermatol Reports (2026) — summary generated from the PubMed abstract.
- 2026
- n = 609
Dermatol Reports - Level ASystematic ReviewPubMed
Regeneration in Aesthetic Medicine: Mechanisms, Evidence, and Clinical Boundaries.
Systematic Review on Skin Aging, Immune Modulation, published in J Cosmet Dermatol (2026) — summary generated from the PubMed abstract.
- 2026
J Cosmet Dermatol - Level ASystematic ReviewEurope PMC
Molecular and Regenerative Effects of Platelet-Rich Plasma and Related Hemocomponents in Animal Models of Liver Injury-A Systematic Review
Systematic Review on Immune Modulation, published in Int J Mol Sci (2026) — summary generated from the PubMed abstract.
- 2026
Int J Mol Sci - Level ASystematic ReviewPubMed
Stromal Vascular Fraction in Bone Healing: A Systematic Review of Clinical Evidence and Potential Implications in Skull Base Reconstruction and Cranioplasty.
Systematic Review with a reported sample of 214 on Chronic Wound, Immune Modulation, published in J Craniofac Surg (2026) — summary generated from the PubMed abstract.
- 2026
- n = 214
J Craniofac Surg - Level AMeta-analysisEurope PMC
The efficacy and safety of MSCs in GVHD prevention and the treatment of SR-aGVHD: a systematic review and meta-analysis of randomized controlled trials
Meta-analysis on Immune Modulation, published in Stem Cell Res Ther (2026) — summary generated from the PubMed abstract.
- 2026
Stem Cell Res Ther - Level ASystematic ReviewEurope PMC
Harnessing exosomes in dry eye disease: a triple threat approach
Systematic Review on Neuroinflammation, Chronic Inflammation, Immune Modulation, published in BMC Ophthalmol (2026) — summary generated from the PubMed abstract.
- 2026
BMC Ophthalmol